<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03591406</url>
  </required_header>
  <id_info>
    <org_study_id>VIT-IRON-2011-004</org_study_id>
    <nct_id>NCT03591406</nct_id>
  </id_info>
  <brief_title>To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia</brief_title>
  <official_title>An Open-label, Randomised Controlled Multi-centre Study to Assess the Impact of Ferric Carboxymaltose in Correcting Iron Deficiency Anaemia Compared With Venofer® (Iron Sucrose) in Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vifor (International) Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vifor (International) Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective is to demonstrate the efficacy of ferric carboxymaltose (FCM) given in
      a simple dosing regimen in correcting iron deficiency anaemia (IDA), by demonstrating
      non-inferiority to treatment with the currently approved intravenous (IV) iron therapy of
      iron sucrose (IS, Venofer™) in the Chinese population. The secondary objectives are to assess
      the safety of FCM compared to IS in the Chinese population and to evaluate the effect of FCM
      compared to IS on relevant laboratory parameters (haematology, chemistry, iron parameters) in
      the Chinese population.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, randomised controlled study to assess the impact of FCM in correcting
      iron deficiency anaemia compared with Venofer™ (IS).

      All subjects, after providing written informed consent and meeting the eligibility
      assessments, will receive a first dose of IV iron as either FCM or IS. A total of
      approximately 368 subjects (184 per group) will be enrolled. All subjects will have iron
      deficiency anaemia as measured by haemoglobin (Hb), serum ferritin and transferrin saturation
      (TSAT) at screening.

      Ferric carboxymaltose will be administered as either a diluted infusion or undiluted
      injection (at Investigator discretion) and IS will be administered as a slow intravenous
      injection at a rate of 1 ml undiluted solution per minute (with each single injection of 200
      mg iron) or by drip infusion. Note, for subjects randomised to receive IS dosing visits are
      required three times a week to achieve total iron repletion dosing as calculated using the
      Ganzoni formula.

      For subjects randomised to FCM, the total iron requirements will be calculated at screening
      based on the screening Hb and subject weight. Dosing will be at baseline and, if required, at
      day 8 and day 15. All subjects will attend study visits at screening, baseline and thereafter
      at Weeks 2, 4 and 6. All subjects will attend an end of study visit (at Week 8 - or earlier
      if discontinued prematurely).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Actual">February 25, 2019</completion_date>
  <primary_completion_date type="Actual">February 25, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Open-label, parallel design, randomised controlled multi-centre trial in Chinese subjects</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8</measure>
    <time_frame>From baseline at any time up to Week 8</time_frame>
    <description>Haemoglobin (Hb)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants Achieving an Increase in Hb of at Least 2 g/dL From Baseline to Weeks 2, 4, 6 and 8</measure>
    <time_frame>From Baseline to weeks 2, 4, 6 and 8</time_frame>
    <description>Haemoglobin (Hb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Hb From Baseline to Weeks 2, 4, 6, and 8</measure>
    <time_frame>From Baseline to weeks 2, 4, 6 and 8</time_frame>
    <description>Haemoglobin (Hb)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Iron Deficiency Correction Over Time by Treatment</measure>
    <time_frame>From Baseline to Weeks 2, 4, 6 and 8</time_frame>
    <description>Iron deficiency correction: TSAT &gt;= 16% and serum ferritin &gt;=100ng/mL (for subjects with underlying inflammatory disease) or &gt;14ng/mL (for subjects with no apparent underlying inflammatory disease).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in TSAT From Baseline to Weeks 2, 4, 6 and 8</measure>
    <time_frame>From Baseline to weeks 2, 4, 6 and 8</time_frame>
    <description>Transferrin saturation (TSAT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Ferritin From Baseline to Weeks 2, 4, 6 and 8</measure>
    <time_frame>From Baseline to Weeks 2, 4, 6 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Iron From Baseline to Weeks 2, 4, 6 and 8</measure>
    <time_frame>From Baseline to weeks 2, 4, 6 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With Any Treatment Emergent Adverse Event (TEAE)</measure>
    <time_frame>From Baseline to the End of the study (week 8)</time_frame>
    <description>Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participant, in particular, the number of participants with at least one TEAE until end of the trial.
Please refer to the detailed tables included on the Adverse Event Module for specifics</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure at Baseline and Weeks 2, 4, 6 and 8</measure>
    <time_frame>Baseline and weeks 2, 4, 6 and 8</time_frame>
    <description>Diastolic Blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Weight at Baseline and Week 8</measure>
    <time_frame>Baseline and week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heart Rate at Baseline and Weeks 2, 4, 6 and 8</measure>
    <time_frame>Baseline and weeks 2, 4, 6 and 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Temperature at Baseline and Weeks 2, 4, 6 and 8</measure>
    <time_frame>Baseline and weeks 2, 4, 6 and 8</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">371</enrollment>
  <condition>Iron Deficiency Anemia</condition>
  <arm_group>
    <arm_group_label>Ferric carboxymaltose (FCM)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects treated with FCM given by IV injection or drip infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Iron sucrose (IS)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects treated with IS given by IV injection or drip infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ferric carboxymaltose</intervention_name>
    <description>Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
    <arm_group_label>Ferric carboxymaltose (FCM)</arm_group_label>
    <other_name>FCM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iron sucrose</intervention_name>
    <description>Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
    <arm_group_label>Iron sucrose (IS)</arm_group_label>
    <other_name>IS</other_name>
    <other_name>Venofer™</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age

          -  Hb &lt;11 g/dL (females) or Hb &lt;12 g/dL (males) at the screening visit

          -  Serum ferritin &lt;100 ng/mL for subjects with underlying inflammatory disease (e.g.,
             inflammatory bowel disease (IBD), chronic kidney disease (CKD) or chronic heart
             failure (CHF), as determined by high sensitive C-reactive protein [hsCRP] levels above
             the normal range) otherwise ≤14 ng/mL in subjects with no apparent underlying
             inflammatory disease (as determined by hsCRP levels within normal range) at the
             screening visit

          -  Transferrin Saturation (TSAT) &lt;16% (any subject) at the screening visit

          -  Microcytic, hypochromic anaemia defined as: a) Mean corpuscular Hb concentration
             (MCHC) &lt;32%; b) Mean corpuscular volume (MCV) &lt; 80 fL; c)Mean corpuscular Hb (MCH) &lt;27
             pg

          -  Subjects with the ability to understand the requirements of the study and abide by the
             study restrictions, and who agree to return for the required assessments

          -  Before any study-specific procedure is conducted, the appropriate written informed
             consent must be obtained

        Exclusion Criteria:

          -  Subject has known hypersensitivity to any of the products to be administered during
             dosing

          -  Any history of iron storage diseases such as haemochromatosis

          -  Any history or clinical findings of iron utilisation disorders such as sideroachrestic
             anaemia

          -  Known haemoglobinopathy (e.g. thalassaemia)

          -  Any history or clinical findings of anaemia associated with: a) Haematuria b) Vitamin
             B12 or folic acid deficiency that requires treatment (subjects can be included after
             deficiency is corrected)

          -  Any allergic predispositions, i.e. any history of asthma or atopic allergy. This
             includes drug allergies.

          -  Planned surgery with anticipated blood loss (defined as Hb drop &gt;2 g/dL) in the 3
             months post randomisation

          -  Subject has known malignancy (with or without current treatment), except basal cell or
             squamous cell carcinoma of the skin or cervical intra-epithelial neoplasia

          -  Haemodialysis (current or planned within the next 3 months)

          -  History of IV iron therapy, erythropoiesis stimulating agent (ESA) therapy and/or
             blood transfusion in previous 4 weeks prior to screening, and oral iron or oral
             iron-containing products including Chinese herbal medicines (&gt;75mg iron/day) in the 7
             days prior to screening

          -  Body weight &lt;35 kg

          -  Chronic liver disease and/or screening alanine transaminase (ALT) or aspartate
             transaminase (AST) above 3 times the upper limit of the normal range

          -  Known human immunodeficiency virus infection, acquired immunodeficiency syndrome,
             tuberculosis

          -  Known active hepatitis B or C or other active infection (acute or chronic)

          -  Subject currently is enrolled in or has not yet completed at least 30 days since
             ending other investigational device or drug study(ies), or subject is receiving other
             investigational agent(s)

          -  Subject is pregnant or is breast feeding

          -  Female subject of childbearing potential not using adequate contraceptive methods
             during the study and for up to 1 month after the last dose of the study medication.
             Adequate contraceptive methods are defined as those which result in a low failure rate
             (i.e., less than 1% per year) when used consistently and correctly such as implants,
             injectables, combined oral contraceptives, some intra-uterine devices, sexual
             abstinence or vasectomised partner. Non-childbearing potential includes being
             surgically sterilised at least 6 months prior to the study or post-menopausal, defined
             as amenorrhoea for at least 12 months

          -  Male subjects planning to father a child within 7 days from the last study drug
             administration.

          -  Subject has any kind of disorder that compromises the ability of the subject to give
             written informed consent and/or to comply with study procedures and/or other reason(s)
             that render subject not appropriate for study participation in the opinion of the
             treating physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jie Jin</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, Zhejiang University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zhihua Ran</last_name>
    <role>Principal Investigator</role>
    <affiliation>Renji Hospital Shanghai Jiaotong Uniersity School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310003</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>June 22, 2018</study_first_submitted>
  <study_first_submitted_qc>July 6, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2018</study_first_posted>
  <results_first_submitted>April 30, 2020</results_first_submitted>
  <results_first_submitted_qc>April 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 18, 2020</results_first_posted>
  <last_update_submitted>April 30, 2020</last_update_submitted>
  <last_update_submitted_qc>April 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Anemia, Iron-Deficiency</mesh_term>
    <mesh_term>Deficiency Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ferric Oxide, Saccharated</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 14, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03591406/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 19, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT03591406/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Subjects who provided signed and dated informed consent were screened within 7 days prior to initial treatment administration.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ferric Carboxymaltose (FCM)</title>
          <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject Body Weight (BW) and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
        </group>
        <group group_id="P2">
          <title>Iron Sucrose (IS)</title>
          <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="188"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="181"/>
                <participants group_id="P2" count="174"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Demography and baseline characteristics for the Safety Set (SS) are provided. The SS was defined as all randomised subjects who received at least 1 dose of study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Ferric Carboxymaltose (FCM)</title>
          <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
        </group>
        <group group_id="B2">
          <title>Iron Sucrose (IS)</title>
          <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="187"/>
            <count group_id="B2" value="180"/>
            <count group_id="B3" value="367"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39.9" spread="9.85"/>
                    <measurement group_id="B2" value="38.9" spread="8.70"/>
                    <measurement group_id="B3" value="39.4" spread="9.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="173"/>
                    <measurement group_id="B2" value="169"/>
                    <measurement group_id="B3" value="342"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="367"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="187"/>
                    <measurement group_id="B2" value="180"/>
                    <measurement group_id="B3" value="367"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Haemoglobin</title>
          <units>g/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.74" spread="1.491"/>
                    <measurement group_id="B2" value="8.06" spread="1.453"/>
                    <measurement group_id="B3" value="7.90" spread="1.479"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum ferritin</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.47" spread="2.145"/>
                    <measurement group_id="B2" value="4.93" spread="6.095"/>
                    <measurement group_id="B3" value="4.70" spread="4.534"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Transferrin saturation (TSAT)</title>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.82" spread="1.898"/>
                    <measurement group_id="B2" value="4.92" spread="2.912"/>
                    <measurement group_id="B3" value="4.87" spread="2.446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>High-sensitivity C-reactive protein (hsCRP)</title>
          <units>mg/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.026" spread="2.1432"/>
                    <measurement group_id="B2" value="1.567" spread="5.9817"/>
                    <measurement group_id="B3" value="1.291" spread="4.4617"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8</title>
        <description>Haemoglobin (Hb)</description>
        <time_frame>From baseline at any time up to Week 8</time_frame>
        <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8</title>
          <description>Haemoglobin (Hb)</description>
          <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="176"/>
                    <measurement group_id="O2" value="175"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>Pre-defined non-inferiority margin of −15%</non_inferiority_desc>
            <param_type>Difference in proportions</param_type>
            <param_value>1.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.15</ci_lower_limit>
            <ci_upper_limit>4.71</ci_upper_limit>
            <estimate_desc>2-sided 95% Confidence Interval (CI) was computed using the Wilson score method with continuity correction described by Newcombe.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants Achieving an Increase in Hb of at Least 2 g/dL From Baseline to Weeks 2, 4, 6 and 8</title>
        <description>Haemoglobin (Hb)</description>
        <time_frame>From Baseline to weeks 2, 4, 6 and 8</time_frame>
        <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants Achieving an Increase in Hb of at Least 2 g/dL From Baseline to Weeks 2, 4, 6 and 8</title>
          <description>Haemoglobin (Hb)</description>
          <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="150"/>
                    <measurement group_id="O2" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="167"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Hb From Baseline to Weeks 2, 4, 6, and 8</title>
        <description>Haemoglobin (Hb)</description>
        <time_frame>From Baseline to weeks 2, 4, 6 and 8</time_frame>
        <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Hb From Baseline to Weeks 2, 4, 6, and 8</title>
          <description>Haemoglobin (Hb)</description>
          <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.01" spread="1.135"/>
                    <measurement group_id="O2" value="2.53" spread="1.016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="172"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.46" spread="1.502"/>
                    <measurement group_id="O2" value="4.08" spread="1.217"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="173"/>
                    <count group_id="O2" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.96" spread="1.435"/>
                    <measurement group_id="O2" value="4.61" spread="1.422"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.09" spread="1.504"/>
                    <measurement group_id="O2" value="4.87" spread="1.525"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Iron Deficiency Correction Over Time by Treatment</title>
        <description>Iron deficiency correction: TSAT &gt;= 16% and serum ferritin &gt;=100ng/mL (for subjects with underlying inflammatory disease) or &gt;14ng/mL (for subjects with no apparent underlying inflammatory disease).</description>
        <time_frame>From Baseline to Weeks 2, 4, 6 and 8</time_frame>
        <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Iron Deficiency Correction Over Time by Treatment</title>
          <description>Iron deficiency correction: TSAT &gt;= 16% and serum ferritin &gt;=100ng/mL (for subjects with underlying inflammatory disease) or &gt;14ng/mL (for subjects with no apparent underlying inflammatory disease).</description>
          <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="170"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="165"/>
                    <measurement group_id="O2" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="161"/>
                    <measurement group_id="O2" value="163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="162"/>
                    <measurement group_id="O2" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in TSAT From Baseline to Weeks 2, 4, 6 and 8</title>
        <description>Transferrin saturation (TSAT)</description>
        <time_frame>From Baseline to weeks 2, 4, 6 and 8</time_frame>
        <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in TSAT From Baseline to Weeks 2, 4, 6 and 8</title>
          <description>Transferrin saturation (TSAT)</description>
          <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
          <units>Percentage of TSAT</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.16" spread="11.741"/>
                    <measurement group_id="O2" value="25.03" spread="19.474"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.00" spread="8.528"/>
                    <measurement group_id="O2" value="25.30" spread="8.453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.50" spread="9.097"/>
                    <measurement group_id="O2" value="23.33" spread="7.868"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.32" spread="10.793"/>
                    <measurement group_id="O2" value="20.82" spread="7.618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Ferritin From Baseline to Weeks 2, 4, 6 and 8</title>
        <time_frame>From Baseline to Weeks 2, 4, 6 and 8</time_frame>
        <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Ferritin From Baseline to Weeks 2, 4, 6 and 8</title>
          <population>Per Protocol Set: participants who were randomised, received at least 1 dose of study treatment, had at least 1 baseline and post-baseline value (Hb, ferritin, TSAT), had a study drug compliance between 80% and 120% and had no major protocol violations</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="178"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="176"/>
                    <count group_id="O2" value="177"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="759.72" spread="331.118"/>
                    <measurement group_id="O2" value="385.51" spread="145.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.31" spread="195.415"/>
                    <measurement group_id="O2" value="280.58" spread="148.913"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="174"/>
                    <count group_id="O2" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.71" spread="152.582"/>
                    <measurement group_id="O2" value="184.93" spread="100.677"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="175"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="202.09" spread="148.382"/>
                    <measurement group_id="O2" value="145.56" spread="89.890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Iron From Baseline to Weeks 2, 4, 6 and 8</title>
        <time_frame>From Baseline to weeks 2, 4, 6 and 8</time_frame>
        <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Iron From Baseline to Weeks 2, 4, 6 and 8</title>
          <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.53" spread="7.075"/>
                    <measurement group_id="O2" value="16.23" spread="14.512"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="178"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.31" spread="4.209"/>
                    <measurement group_id="O2" value="12.39" spread="4.724"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="172"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.77" spread="4.318"/>
                    <measurement group_id="O2" value="11.27" spread="4.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.77" spread="4.871"/>
                    <measurement group_id="O2" value="10.09" spread="4.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With Any Treatment Emergent Adverse Event (TEAE)</title>
        <description>Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participant, in particular, the number of participants with at least one TEAE until end of the trial.
Please refer to the detailed tables included on the Adverse Event Module for specifics</description>
        <time_frame>From Baseline to the End of the study (week 8)</time_frame>
        <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With Any Treatment Emergent Adverse Event (TEAE)</title>
          <description>Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participant, in particular, the number of participants with at least one TEAE until end of the trial.
Please refer to the detailed tables included on the Adverse Event Module for specifics</description>
          <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure at Baseline and Weeks 2, 4, 6 and 8</title>
        <description>Diastolic Blood pressure</description>
        <time_frame>Baseline and weeks 2, 4, 6 and 8</time_frame>
        <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure at Baseline and Weeks 2, 4, 6 and 8</title>
          <description>Diastolic Blood pressure</description>
          <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.8" spread="7.91"/>
                    <measurement group_id="O2" value="71.9" spread="8.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.0" spread="8.33"/>
                    <measurement group_id="O2" value="72.6" spread="8.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.1" spread="7.60"/>
                    <measurement group_id="O2" value="73.8" spread="9.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.6" spread="8.18"/>
                    <measurement group_id="O2" value="74.3" spread="9.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="8.09"/>
                    <measurement group_id="O2" value="74.1" spread="9.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Weight at Baseline and Week 8</title>
        <time_frame>Baseline and week 8</time_frame>
        <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Weight at Baseline and Week 8</title>
          <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.76" spread="9.384"/>
                    <measurement group_id="O2" value="60.40" spread="9.354"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.73" spread="9.316"/>
                    <measurement group_id="O2" value="60.64" spread="9.372"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Heart Rate at Baseline and Weeks 2, 4, 6 and 8</title>
        <time_frame>Baseline and weeks 2, 4, 6 and 8</time_frame>
        <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Heart Rate at Baseline and Weeks 2, 4, 6 and 8</title>
          <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
          <units>beats/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.4" spread="8.85"/>
                    <measurement group_id="O2" value="82.2" spread="9.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.3" spread="9.80"/>
                    <measurement group_id="O2" value="76.5" spread="8.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" spread="10.71"/>
                    <measurement group_id="O2" value="76.6" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.0" spread="8.98"/>
                    <measurement group_id="O2" value="77.2" spread="10.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.8" spread="10.33"/>
                    <measurement group_id="O2" value="77.5" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Temperature at Baseline and Weeks 2, 4, 6 and 8</title>
        <time_frame>Baseline and weeks 2, 4, 6 and 8</time_frame>
        <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
        <group_list>
          <group group_id="O1">
            <title>Ferric Carboxymaltose (FCM)</title>
            <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
          </group>
          <group group_id="O2">
            <title>Iron Sucrose (IS)</title>
            <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Body Temperature at Baseline and Weeks 2, 4, 6 and 8</title>
          <population>Safety Set: all randomised participants who have received at least 1 dose of study medication. The participants in this group were analysed based on the treatment they received.</population>
          <units>ºC</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="187"/>
                <count group_id="O2" value="180"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="187"/>
                    <count group_id="O2" value="180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.94" spread="0.292"/>
                    <measurement group_id="O2" value="36.45" spread="0.325"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="185"/>
                    <count group_id="O2" value="179"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.48" spread="0.269"/>
                    <measurement group_id="O2" value="36.44" spread="0.288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="179"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.49" spread="0.269"/>
                    <measurement group_id="O2" value="36.40" spread="0.268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="180"/>
                    <count group_id="O2" value="173"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.47" spread="0.259"/>
                    <measurement group_id="O2" value="36.41" spread="0.260"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="181"/>
                    <count group_id="O2" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.48" spread="0.269"/>
                    <measurement group_id="O2" value="36.46" spread="0.257"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline until the End of the Study (8 weeks)</time_frame>
      <desc>All AEs either observed by the Investigator/collaborators, or reported by the subject spontaneously, or in response to a direct question, were noted in the AE section of the case report form/source document. In order to avoid bias in eliciting AEs, subjects were asked a non-leading question, such as “How are you feeling?” A non-leading question was used as well for changes in their health or concomitant medication usage since their last visit. This information was collected at all study visits.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ferric Carboxymaltose (FCM)</title>
          <description>Participants treated with FCM given by IV injection or drip infusion
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection
Strength: 10 mL vials containing 500 mg iron per vial
Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening)
Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline)
Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.</description>
        </group>
        <group group_id="E2">
          <title>Iron Sucrose (IS)</title>
          <description>Participants treated with IS given by IV injection or drip infusion
Dosage Form: Sterile solution for injection containing 2% w/v iron
Strength: 5 mL ampoules containing 100 mg iron per ampoule
Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit [mg] = BW [kg] x (target Hb- actual Hb) [g/dL] x 2.4 + 500 mg, up to 11 IS injections will be given
Route of administration: IV injection or drip infusion
Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 19.1.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Anaphylactic shock</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gastric cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Adenomyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Pelvic adhesions</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2.0</frequency_threshold>
        <default_vocab>MedDRA version 19.1.</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="187"/>
                <counts group_id="E2" subjects_affected="92" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="187"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="187"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" events="16" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E2" events="12" subjects_affected="9" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="187"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Urine phosphorus decreased</sub_title>
                <counts group_id="E1" events="18" subjects_affected="14" subjects_at_risk="187"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="11" subjects_at_risk="187"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="187"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyl transferase increased</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="187"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="20" subjects_affected="19" subjects_at_risk="187"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="187"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="180"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="187"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="180"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Emanuele Noseda, PharmD - Global Clinical Research Director</name_or_title>
      <organization>Vifor Pharma Management</organization>
      <phone>+41 58 851 80 00</phone>
      <email>emanuele.noseda@viforpharma.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

